Business Context and Reporting Period
This Form 8-K filing by vTv Therapeutics Inc. (VTVT) covers the reporting period ending December 11, 2023. The Company is incorporated in Delaware and its Class A common stock trades on the Nasdaq Capital Market. The report addresses regulatory compliance status regarding Nasdaq listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status events rather than financial performance data.
Material Changes
The primary material event is the Company regaining compliance with the Nasdaq Minimum Bid Requirement as of December 8, 2023. Previously, the Company received a deficiency letter on December 22, 2022, due to its stock closing below $1.00 for 30 consecutive business days. The Company was granted an extension until December 18, 2023, and subsequently effected a reverse stock split on November 20, 2023, to meet the requirement.
Outlook, Risks, and Management Commentary
Nasdaq has confirmed that the listing of the Company's common stock on the Nasdaq Capital Market will continue following the regained compliance. The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the historical context of the listing deficiency.
Investor Verification Checklist
- Verify the current trading price of VTVT to ensure continued compliance with the $1.00 minimum bid requirement.
- Review the November 20, 2023, Form 8-K for details regarding the reverse stock split ratio and its impact on share count.
- Confirm the Company's cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not disclose liquidity metrics.